ognizant Communication Corporation

ONCOLOGY RESEARCH
AN INTERNATIONAL JOURNAL
INCORPORATING ANTI-CANCER DRUG DESIGN

AUTHOR AND SUBJECT INDEXES

VOLUME 14

Author Index

Aggelakis, F., 439
Agnanti, N. J., 439
Akiyama, S., 39
Alvero, A. B., 567
Antony, V. B., 155
Aoki, S., 39
Arlucea, J., 363
Asumendi, A., 363

Bäckström, T., 321
Baba, M., 39
Baguley, B. C., 75, 297
Bailly, C., 235
Baker, A. F., 513
Balzarotti, M., 325
Bastert, G., 603
Bertino, J. R., 373
Bharathy, S., 61
Bisikirska, B., 133
Bloomer, W. D., 21
Boiardi, A., 325
Bologna, M., 101
Bordonaro, M., 427
Borowski, E., 469
Bossemeyer, D., 267
Bowman, E. D., 315
Boyano, M. D., 363
Bravo-Otero, E., 315
Breitenlechner, C., 267
Brown, L. M., 315
Butler, S. A., 93

Calatozzolo, C., 325
Cañete, A., 291
Capasso, F., 415
Carbone, R., 427
Cardile, V., 415
Castel, V., 291
Catanzaro, R. P., 133
Cavallaro, E., 579
Cecchi, F., 501
Chakraborty, A. K., 163
Chen, L., 355
Chen, W., 567
Ching, L.-M., 75
Cho, H. Y., 491
Choe, Y. H., 455
Choi, M. M., 227
Christensen, I. J., 611
Chung, F., 75
Chung, K. H., 227
Ciusani, E., 325
Cole, P., 373
Conney, A. H., 387
Conover, C. D., 455
Consoli, R., 415
Coon, A., 513
Cortes, D., 147
Coutts, R., 297
Croci, D., 325
Cuevas, C., 579
Cusano, G., 345
Cutts, S. M., 279

Damia, G., 579
Dardoufas, K., 439
Dassonneville, L., 235
Davilas, E., 439
Delipetar-Grudl, A., 559
de Rossi, T. M., 603
Diehl, S. R., 315
Di Francesco, A. M., 579
D'Incalci, M., 579
Ding, Y., 355
Di Silvio, A., 579
Dondi, D., 101
Duhé, R. J., 175
Dunne, A. L., 447
Dwipoyono, B., 567

Ehrsson, H., 113
Eichbaum, M. H. R., 603
Engh, R., 267
Erba, E., 579
Espreafico, E. M., 163

Faircloth, G. T., 579
Fenaux, P., 235
Ferlini, C., 345
Ferlini, C., 83
Fernández, J. M., 291
Ferrandina,G., 83
Ferrante, Jr., A. W., 133
Festuccia, C., 101
Finch, R. A., 331
Franchina, M., 399
French, K. J., 49
Fu, L., 355
Fuente-Pinedo, M. de la, 363
Furneaux, C. E., 297
Furukawa, T., 39

Gaßel, M., 267
Gallardo, T., 147
Gard, J. M., 513
Garg, M., 567
George, B. L., 513
Getoff, N., 559
Gilmore, J. L., 589
Gorlick, R., 373
Grau, E., 291
Greenwald, R. B., 455
Gridley, G., 315
Gu, B., 373
Gu, L.-Q., 355
Guan, S., 455
Guerini, V., 101
Gullbo, J., 113
 
 

Ha, W. S., 491
Haffty, B. G., 61
Hage, C., 155
Hao, X.-Y., 567
Haraguchi, M., 39
Hardwick, J., 155
Harris, A. L., 529
Harris, P. E., 133
Hayes, R. B., 315
Heider, I., 475
Hellberg, D., 321
Henklein, P., 475
Hernández, P., 147
Hesdorffer, C. S., 133
Hirata, K., 407
Hirst, D. G., 447, 483
Hou, L., 315
Huang, M.-T., 387
Huyghe, P., 235

Ihle, N., 513
Iles, R. K., 93
Inoue, Y., 407
Isaacs, R. J., 297
Itoh, H., 407
Ivery, M. T. G., 1
Izotova, L., 541

Jang, J. S., 491
Jangi, S.-M., 363
Ji, M., 21
Johnson, D. R., 331
Johnson, L. K., 331
Jose, C. C., 297

Kalb, E. N., 305
Kamsteeg, M., 567
Karabulut, B., 381
Karydas, I., 439
Katsuki, T., 407
Kaufmann, R., 475
Kaul, S., 603
Kay, P. H., 399
Kerrigan, J. E., 541
Kestell, P., 75
Kim, D., 61
Kim, D. S., 227
Kim, H. S., 227
Kim, H. W., 491
Kim, K. S., 227
Kim, S. I., 227
Kirker, J. A., 297
Kirkpatrick, L., 513
Kizoulis, M., 387
Kobayashi, M., 39
Koeffler, H. P., 345
Kohno, K., 407
Kolesnikova, N., 163
Kolipanos, A., 439
Kumar, R., 247

Larsson, R., 113
Lavoie, T. B., 541
Lazarova, D. L., 427
Lazo, J. S., 305
Le, T., 1
Lee, B. D., 49
Lee, Y. J., 491
Leffert, J. J., 331
Lewensohn, R., 113
Li, W., 373
Liang, Y., 355
Lin, C. B., 387
Lin, Z. P., 331
Lindström, A. K., 321
Longley, C. B., 455
Lown, J. W., 247
Lowndes, S. A., 529
Luthman, K., 113
Lykke, J., 611

Maffei, A., 133
Mahadevan, D., 513
Mamoon, N. M., 175
Man, H.-W., 75
Mantovani, R., 579
Marshall, E. S., 297
Martin, D. S., 373
Martínez, F., 291
Mastrangelo, R., 345
Matthews, J. H. L., 297
McKiernan, J. M., 133
Meuillet, E. J., 513
Minagawa, N., 407
Mitsuo, M., 39
Mizobuchi, H., 373
Mohammed, K. A., 155
Mor, G., 567
Morales, M. C., 363
Mori, M., 31
Morosetti, R., 345
Morton, R. P., 297
Moschella, F., 133
Mothersill, C., 447
Motta, M., 101
Muller, G. W., 75
Muramatsu, T., 331

Nagata, N., 407
Nagata, Y., 39
Nakajima, Y., 39
Nakayama, Y., 407
Nasioulas, G., 439
Nasreen, N., 155
Nielsen, H. J., 611
Nieto, N., 363
Noguchi, T., 39
Nudelman, A., 279
Nygren, P., 113
 

 

Ohie, S., 407
Okamura, S., 31
Oktem, G., 381
Oltra, S., 291
O'Malley, D., 567
Omay, S. B., 381
Onitsuka, K., 407
Orellana, C., 291
Oshimoto, H., 31
Oswald, E., 475

Pacini, S., 501
Paine, M. J. I., 469
Palmer, B. D., 75
Papadapoulos, K. P., 133
Papadopoulou, E., 439
Papadopoulou, M. V., 21
Park, Y. S., 227
Parker, B. S., 279
Pawlowska, J., 469
Pawelek, J., 163
Peláez, F., 147
Perez-Yarza, G., 363
Peronni, K. C., 163
Peruzzi, B., 501
Pestka, S., 541
Phillips, D. R., 279
Pini, J. T., 399
Pizzorno, G., 331
Poletti, A., 101
Powis, G., 513
Priebe, W., 469

Rai, D., 247
Ramirez-Icaza, C., 155
Ranelletti, F. O., 83
Rao, M. K., 21
Raspaglio, G., 83
Reiss, M., 61
Ren, X.-Q., 39
Renis, M., 415
Rephaeli, A., 279
Riccardi, R., 579
Rice, M. L., 297
Riese, II, D. J., 589
Rimm, D. L., 61
Robson, T., 447
Royo, I., 147
Ruan, J., 355
Ruddock, M. W., 483
Ruggiero, M., 501
Russo, A., 415
Rutherford, T., 567

Sako, T., 407
Salmaggi, A., 325
Sanders, K., 155
Sanli, U. A., 381
Sapi, E., 567
Sartorelli, A. C., 331, 427
Sawczuk, I. S., 133
Scaccianoce, E., 101
Scambia, G., 83, 345
Scheele, J., 475
Schulze, B., 475
Schwartz, B., 541
Scifo, C., 415
Seiberg, M., 387
Selvi, N., 381
Servidei, T., 345
Sezgin, C., 381
Shapiro, S., 387
Shaw, J. H. F., 297
Shi, Z., 355
Shibao, K., 407
Shields, P. G., 315
Smith, C. D., 49
Smith, J. K., 175
Sotiriou, V., 439
Sousa, J. F., 163
Sriram, P. S., 155
Staite, E. M., 93
Stamper, C., 513
Stendahl, U., 321
Su, D., 373
Sumizawa, T., 39
Svendsen, M. N., 611

Tarasiuk, J., 469
Taylor, J. M. E., 399
Tormo, J. R., 147
Tsurudome, Y., 407
Tullberg, M., 113

Uslu, R., 381

Våbenø, J., 113
Vancheri, C., 415
Vanella, A., 415
Van Horn, R. D., 155
Vannucchi, S., 501
Vogt, A., 305

Wang, X., 355
Werther, K., 611
White, J. B., 297
Whittaker, J. R., 297
Williams, R., 513
Wilson, G. D., 447
Winn, D. M., 315
Wolf, C. R., 469
Wu, W., 541
Wu, X.-P., 355

Xia, J., 455
Xie, H., 315
Xie, J.-G., 387
Xie, W., 61

Yadav, P., 541
Yoshida, M., 31
Yurtseven, M. E., 381

Zafra-Polo, M. C., 147
Zhao, H., 455
Zhao, Q., 455
Zhuang, Y., 49

Subject Index

Acetogenins, 147
Adenocarcinoma, 321
Adhesion molecules, 603
Agosterol A (AG-A), 39
Akt, 513
L-Alanosine, 373
Alkylating peptides, 113
AN-9, 279
Androgen receptor, 101
Angiogenesis, 155, 501, 529
Antagonist, 589
Antiangiogenesis, 227
Antiangiogenic therapy, 529
Anticancer agents, 305
Anticancer treatment, 93
Antitumor activity, 513
Apoptosis, 83, 235, 297, 345, 363, 447
Autoantigens, 133

Bcl-2, 235
Benzyl elimination, 455
Biomarker, 491
Bioreductive drug, 21
Butyrate, 427

Cancer, 147, 267
Cancer chemoprevention, 387
Carcinoembryonic antigen (CEA), 439
Carcinoma, 315
Cationic liposomes, 227
cDNA microarray, 133
Cehmosensitizer, 567
Cell cycle, 235, 345, 579
Cell lines, 113
Cervix neoplasms, 321
Chelation, 529
Chemotherapy, 567
Cimetidine, 363
Cis-platinum, 325
c-Met proto-oncogene, 163
Colon 38, 75
Colon cancer, 407, 427, 447
Colon carcinoma, 475
Colorectal cancer, 31
Copper, 529
Crystal structure, 267
Cystine knot growth factor, 93
Cytostatic efficiency, 559
Cytotoxic potency, 247
Cytotoxicity, 113, 147, 305, 381

Daunorubicin, 469
Decitabine, 279
D-3-Deoxy-phosphatidyl-myo-inositol ether lipid, 513
Diphenhydramine, 363
Disintegrin, 227
DMXAA, 75
DNA adducts, 279
DNA methylation, 279
DNA quantification, 439
Docetaxel, 381, 447
Doxorubicin, 325, 355, 381
Drug binding site, 39
Drug sensitivity, 373
DU145, 415
DU145 cells, 101

Enantiomers, 75
Endostatin, 155
Enzymatic reduction, 21
Enzymes, 315
Epidermal growth factor, 83
ErbB3, 589
ErbB4, 589
E-selectin, 603
ET-743 analog, 579

Folic acid (vitamin B11), 559
Free hCGb, 93
 
 
 
 

 

G2/M block, 447
Gene therapy, 227, 427
Genomic hypomethylation, 399
Glioma, 325
Glutathione-S-transferase P1 (GSTP1), 439
Glycosaminoglycans, 501

Head and neck cancer, 61
Heparin, 501
High-content screening, 305
Histamine antagonist, 363
Human plasma, 501
Human prostate cancer, 415
Human tumors, 297
Hybrid, 163
Hydroxyurea, 235
Hypermethylation, 399
Hypoxic cytotoxin, 21

Imidazole, 355
Inducible nitric oxide synthase (iNOS), 381
Inhibition of growth, 345
Inhibitor selectivity, 267
Interphase cell death, 297

J1, 113

Lithium, 427
Liver metastases, 603
Locoregional, 325

Malignant lymphoproliferative disorders, 399
MCF-7, 381
Melanocyte-stimulating hormone (MSH), 163
Melphalan, 113
6-Mercaptopurine, 455
Metastasis, 155, 163
Metastatic breast cancer, 603
Methylmercaptopurine riboside (MMPR), 373
Methylthioadenosine phosphorylase (MTAP), 373
Micrometastasis, 291
Microtubules, 1
Minimal residual disease, 291
Mitochondrial respiratory chain inhibitors, 147
Mitochondrion, 363
Mitogen-activated protein kinases, 83
Mitoxantrone, 279
Molecular marker, 291
Molecular modeling, 1, 541
Molecularly targeted PTKI therapy, 175
Motility, 163
Mouse solid tumor model, 49
Mrp1, 331
Multidrug resistance, 49, 331, 355
Mutagenesis, 267
Myf-3, 399
Myosin light chain kinase, 483
Myosin light chains, 483

NADH dehydrogenase, 469
NADPH cytochrome P450 reductase, 469
NAD(P)H oxidation, 469
Neuregulin, 589
Neuroblastoma, 345
Neutrophils, 611
Nicotinamide, 483
Nitric oxide, 381
NLCQ-1, 21
Nondenatured soymilk, 387
Nucleotide excision repair, 579

Ovarian cancer, 155, 567
 

P2, 113
p53, 235
Paclitaxel, 1, 297
PAR1, 475
Parenteral administration, 455
PAX7, 399
Peptichemio, 113
Peptides, 501
P-Glycoprotein (P-gp), 39, 49, 331, 355
Pharmacodynamics, 513
Phenotype, 345
Phenoxodiol, 567
Phosphate stability, 541
Phosphokinase recognition sites, 541
Phospholipase D (PLD), 31
Phospholipase D2 (PLD2), 31
Phosphorylated antibodies, 541
Photoaffinity labeling, 39
Pleural mesothelial cells, 155
Poly(ethylene glycol), 455
Polymorphism, 315
Poor prognosis, 93
Propolis, 415
Prostaglandin J2, 345
Prostate cancer, 101
Prostate-specific membrane antigen (PSMA), 439
Proteinase-activated receptors, 475
Protein kinase C, 475
Protein kinase C inhibitor, 267
Protein-tyrosine kinase inhibitors (PTKIs), 175
Proteolysis, 501
Proteome, 491
PX-316, 513

Quercetin, 83

Radiolysis, 559
Radiophosphate-labeled antibody, 541
Radiosensitivity, 297
Radiosensitization, 447
Radio therapeutic, 541
Reactive oxygen species formation, 469
Rectal cancer, 611
Resveratrol, 415
Rho-kinase inhibitor, 267
Rosiglitazone, 345
RT-PCR, 291

Salmosin, 227
Serine protease inhibitors, 387
Smad, 61
Smoking, 315
Soft tissue sarcoma cells, 373
Squamous cell carcinoma, 321
Stomach cancer, 491
Structure of interaction, 1
Sugar-modified derivatives, 469
Surrogate kinase, 267

TAC-101, 407
Tamoxifen, 83
Targeted cancer therapy, 175
Tcf, 427
Temozolomide, 325
Thalidomide, 75
Tissue microarray, 61
Topical application, 387
Topotecan, 325
Transforming growth factor-b, 61
L-Tryptophan, 247
L-Tryptophan dimmers, 247
L-Tryptophan-polyamide conjugates, 247
b-Tubulin, 1
Tumor antigens, 133
Tumor cell line growth inhibitors, 147
Tumor markers, 603
Tumor necrosis factor, 75
Tumor radiosensitizer, 483
Tumor vessels, 611

Vaccine development, 93
Vaccines, 133
Vascular endothelial growth factor (VEGF), 407, 611
Vascular endothelial growth factor receptor 1, 611
Vascular smooth muscle, 483
Vincristine, 355
Vincristine toxicity, 331
Vinorelbine, 415

Wnt, 427

Xanthine oxidase, 469
X-linked inhibitor of apoptosis protein (XIAP), 567